Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Mesoblast Limited — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.84, while Mesoblast Limited trades at $16.34 (market cap $2.17B). The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | MESO | |
|---|---|---|
52-Week High | $112.91 | $20.96 |
52-Week Low | $106.96 | $12.88 |
Market Cap | — | $2.17B |
Sector | — | Technology |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.
Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
